CurrentBlue Cross Blue Shield - TexasPolicy CPCPLAB043

Evaluation of Dry Eyes

This clinical payment and coding policy governs reimbursement for laboratory testing related to suspected dry eye disease for Blue Cross and Blue Shield of Texas members; it specifies which tear tests are reimbursable and which are not and applies to providers submitting claims to BCBSTX.

Policy Summary

PayerBlue Cross Blue Shield - Texas

PolicyEvaluation of Dry Eyes

Policy CodePolicy CPCPLAB043

Change TypeNo material change

Effective DateAug 8, 2025

Next Review Date

Key ActionSubmit accurate documentation and be prepared to provide additional records upon request for claim review.

SourceLink

POLICY UPDATE CHANGES

No material clinical or coverage changes in this revision.

4tests explicitly addressed

1reimbursable tests

3not reimbursable tests

4procedure codes

1document version

Reimbursement Criteria for Tear Tests

Policy Summary

PayerBlue Cross Blue Shield - Texas

PolicyEvaluation of Dry Eyes

Policy CodePolicy CPCPLAB043

Change TypeNo material change

Effective DateAug 8, 2025

Next Review Date

Key ActionSubmit accurate documentation and be prepared to provide additional records upon request for claim review.

SourceLink

On This Page

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Reimbursement criteria

Reimbursement stance for specific tear tests in individuals suspected of having dry eye:

For individuals suspected of having dry eye, testing of tear osmolarity may be reimbursable when used to determine the severity of dry eye disease or to monitor effectiveness of therapy.

For individuals suspected of having dry eye disease based on comprehensive eye examination, testing for MMP-9 protein in human tears is NOT reimbursable.

For individuals suspected of having dry eye disease, testing for lactoferrin and/or IgE in tears is NOT reimbursable.

For individuals suspected of having dry eye disease, all other testing not discussed above is NOT reimbursable.

Procedure Codes and Coding Notes

Procedure codes listedmixed

82785
83516
83520
83861

Code list completeness note

Code list completenessThe code list is not all-encompassing; inclusion of a code does not guarantee it is a covered service or eligible for reimbursement.

Implication for claimsInclusion on the list does not ensure payment — coverage depends on benefit, contract, and policy review.

Provider actionProviders should verify specific plan documents for coverage eligibility before relying on listed codes.

Documentation, Claims, and Policy Applicability

Documentation Required

Documentation and claim review

Providers must submit accurate documentation for services rendered and code claims using valid, industry‑standard code sets; claims are subject to code edits and review and providers may be asked to submit additional documentation upon request.

Submit claims using valid code combinations from HIPAA‑approved code sets and industry standard coding guidelines (e.g., UB, AMA CPT, HCPCS, ICD‑10).
Claims are subject to code edit protocols and review against benefit coverage, provider contract language, medical policies, CPCPs, and coding software logic.
Provide additional documentation upon request to support the claim.

Denial Risk

Policy applicability and disputes

BCBSTX may interpret and apply this policy with reasonable discretion; if a conflict exists the member’s plan document or a provider contract will govern.

Plan documents (e.g., Certificates, benefit booklets, Summary Plan Descriptions) govern in the event of conflict with this policy.
Provider contracts govern in the event of conflict with this policy where applicable.
BCBSTX has full and final discretionary authority for interpretation and application to the extent allowed by plan documents.

Tests Defined

Tear osmolarity — definition and clinical uses

DefinitionTear osmolarity testing measures the concentration of solutes in the tear film and may be used to assess tear film hyperosmolarity.

Clinical useMay be reimbursable when used to determine the severity of dry eye disease.

MonitoringMay be reimbursable when used to monitor effectiveness of therapy for dry eye disease.

Plan variabilityNot all reimbursement requirements apply to every product; providers should review plan documents for eligibility.

MMP-9 testing — definition and coverage

DefinitionMMP-9 testing refers to point-of-care or laboratory assays that detect matrix metalloproteinase‑9 protein in human tears.

Coverage stancePoint-of-care or laboratory testing for MMP‑9 protein in human tears is NOT reimbursable for individuals suspected of having dry eye disease following a comprehensive eye exam.

ContextApplies to testing done as part of evaluation for suspected dry eye disease; all other testing not discussed is also not reimbursable.

Lactoferrin and IgE testing — definition and coverage

DefinitionLactoferrin and IgE testing refers to assays measuring lactoferrin protein and/or immunoglobulin E in tear fluid.

Coverage stanceTesting for lactoferrin and/or IgE in tears is NOT reimbursable for individuals suspected of having dry eye disease.

ScopeThis non‑reimbursable position applies specifically to evaluation of suspected dry eye disease as described in the policy.